On June 8, the FDA announced the availability of final product-specific BE recommendations, which provide product-specific guidance on the design of BE studies to support abbreviated new drug applications. The FDA also published a separate document proposing additional draft and revised draft product-specific BE recommendations; comments on the draft recommendations will be accepted until September 8, 2009.